Compare Stocks → AI finds its first serious application (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AUPHNYSE:CBMNASDAQ:EIDXNASDAQ:FTSVNASDAQ:PRNB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$4.87-3.2%$5.29$4.71▼$12.43$704.30M1.362.15 million shs1.53 million shsCBMCambrex$59.99$59.99$33.80▼$60.29$2.02B2.14218,726 shsN/AEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/APRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals-1.18%+2.44%+0.80%-37.44%-54.56%CBMCambrex0.00%0.00%0.00%0.00%0.00%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%FTSVForty Seven0.00%0.00%0.00%0.00%0.00%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%The Hard Truth About Investing For Retirement (Ad)Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals1.2581 of 5 stars3.43.00.00.01.10.00.6CBMCambrexN/AN/AN/AN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals2.75Moderate Buy$10.00105.34% UpsideCBMCambrexN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest AUPH, CBM, FTSV, EIDX, and PRNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/1/2024AUPHAurinia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.002/23/2024AUPHAurinia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $10.002/22/2024AUPHAurinia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $13.002/16/2024AUPHAurinia PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold$9.50 ➝ $9.002/16/2024AUPHAurinia PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$13.00 ➝ $8.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$175.51M4.01N/AN/A$2.63 per share1.85CBMCambrex$532.09M3.80$3.91 per share15.36$19.48 per share3.08EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74FTSVForty Seven$15.68M293.33N/AN/A$7.52 per share12.70PRNBPrincipia Biopharma$35.16M94.50N/AN/A$10.95 per share9.14Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals-$78.02M-$0.54N/A8.85N/A-44.45%-20.10%-14.84%5/2/2024 (Confirmed)CBMCambrex$92.41M$2.7721.66∞N/A5.96%5.38%2.50%N/AEIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/AFTSVForty Seven-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/APRNBPrincipia Biopharma-$53.79M-$2.09N/AN/AN/AN/A-23.08%-21.11%N/ALatest AUPH, CBM, FTSV, EIDX, and PRNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/2/2024N/AAUPHAurinia Pharmaceuticals-$0.17N/A+$0.17N/AN/AN/A 2/15/202412/31/2023AUPHAurinia Pharmaceuticals-$0.16-$0.19-$0.03-$0.19$45.00 million$45.10 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ACBMCambrexN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.205.504.99CBMCambrex0.762.371.70EIDXEidos Therapeutics0.1411.1011.10FTSVForty SevenN/A14.8114.81PRNBPrincipia BiopharmaN/A17.0117.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%CBMCambrex90.96%EIDXEidos Therapeutics31.40%FTSVForty Seven71.77%PRNBPrincipia Biopharma95.54%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals4.30%CBMCambrex1.41%EIDXEidos Therapeutics70.10%FTSVForty Seven37.40%PRNBPrincipia Biopharma16.01%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300144.62 million138.40 millionOptionableCBMCambrex1,73233.72 millionN/AOptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionableFTSVForty Seven5748.16 millionN/ANot OptionablePRNBPrincipia Biopharma6533.21 millionN/ANot OptionableAUPH, CBM, FTSV, EIDX, and PRNB HeadlinesSourceHeadlineRecap: Principia pounds Metrostltoday.com - April 24 at 11:37 PMRecap: Principia rips Lutheran Northstltoday.com - April 20 at 10:35 PMRecap: O'Fallon Christian breezes by Principiastltoday.com - April 17 at 7:58 AMPrincipia names Markus Bathelt men's soccer coachthetelegraph.com - April 16 at 3:55 PMRecap: Crystal City slips past Principiastltoday.com - April 16 at 10:54 AMRecap: Lutheran South upends Principiastltoday.com - April 13 at 12:46 PMRecap: Lutheran South breezes by Principiastltoday.com - April 13 at 1:58 AMRecap: Westminster breezes by Principiastltoday.com - April 7 at 9:36 PMRecap: Westminster trounces Principiastltoday.com - April 7 at 9:36 PMRecap: Westminster waltzes over Principiastltoday.com - April 7 at 12:21 AMRecap: Westminster routs Principiastltoday.com - April 7 at 12:21 AMRecap: Principia trounces Gateway Science Academystltoday.com - April 5 at 11:14 PMPrincipia College Promises "Celebration of Humanity" at Annual Dance Productionriverbender.com - April 2 at 12:37 PMJudy Pfaff giving free lecture on installation art at Principia College this weekthetelegraph.com - March 31 at 3:38 PMRecap: MICDS pounds Principiastltoday.com - March 28 at 12:19 AMClass 2 Girls Basketball Championship Game: Skyline 61, Principia 47newstribune.com - March 8 at 10:25 AMPrincipia falls to Skyline in first girls basketball state championship appearancestltoday.com - March 8 at 12:02 AMClass 2 girls basketball state championship: Skyline 61, Principia 47stltoday.com - March 8 at 12:02 AMPrincipia answers Norwood's run to reach girls basketball state final for first timestltoday.com - March 6 at 7:43 PMPrincipia vs. Norwoodstltoday.com - March 6 at 7:43 PMMICDS vs. Principiastltoday.com - March 1 at 1:26 AMPrincipia uses threes to defeat Lady Shamrocksemissourian.com - February 29 at 10:24 AMRecap: Principia handily defeats Bismarckstltoday.com - February 27 at 8:05 AMDasia Scott posts another double-double to lead Principia to sectional win over Bismarckstltoday.com - February 27 at 8:05 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAurinia PharmaceuticalsNASDAQ:AUPHAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.CambrexNYSE:CBMCambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.Eidos TherapeuticsNASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.Forty SevenNASDAQ:FTSVForty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.Principia BiopharmaNASDAQ:PRNBPrincipia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.